Different targets for treating focal segmental glomerular sclerosis

Contributions to Nephrology

Volumn 181, Issue , 2013, Pages 84-90

  Coppo, Rosanna ^a  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CALCINEURIN; CYCLOSPORIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; RITUXIMAB;

ARTICLE; CYTOSKELETON; DRUG ANTAGONISM; DRUG EFFECT; FOCAL GLOMERULOSCLEROSIS; HUMAN; METABOLISM; PHYSIOLOGY; PODOCYTE;

ACTINS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CALCINEURIN; CYCLOSPORINE; CYTOSKELETON; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; METHYLPREDNISOLONE; NF-KAPPA B; PODOCYTES;

EID: 84958632302     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000348637     Document Type: Article

References (40)

1. Hildebrandt F: Genetic kidney diseases. Lancet 2010;375:1287-1295.
2. McCarthy ET, Sharma M, Savin VJ: Circulating permeability factors in idiopathic ne-phrotic syndrome and focal segmental glo-merulosclerosis. Clin J Am Soc Nephrol 2010; 5:2115-2121.
3. Habib R, Churg J: Minimal change disease, mesangial proliferative glomerulonephritis and focal sclerosis: individual entities of a spectrum of disease; in Robison RR (ed): Ne-phrology Today. Proceedings of the Ninth Congress of Nephrology. New York, Springer, 1984, pp 634-644.
4. Niaudet P: Long-term outcome of children with steroid-sensitive idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 2009; 4: 1547-1548.
5. Cunard R, Kelly CJ: T cells and minimal change disease. J Am Soc Nephrol 2002; 13: 1409-1411. (Pubitemid 34441424)
6. Lagrue G, Xheneumont S, Branellec A, Hir-bec G, Weil B: A vascular permeability factor elaborated from lymphocytes. Demonstration in patients with nephrotic syndrome. Bio-medicine 1975; 23:37-40.
7. Matsumoto K, Kanmatsuse K: Transforming growth factor-β #inf#1#/inf# inhibits vascular permeability factor release by T cells in normal subjects and in patients with minimal change ne-phrotic syndrome. Nephron 2001; 87:111-117. (Pubitemid 32215821)
8. Lennon R, Singh A, Welsh GI, Coward RJ, Satchell S, Ni L, Mathieson PW, Bakker WW, Saleem MA: Hemopexin induces nephrin-dependent reorganization of the actin cyto-skeleton in podocytes. J Am Soc Nephrol 2008; 19:2140-2149.
9. Bakker WW, Borghuis T, Harmsen MC, van den Berg A, Kema IP, Niezen KE, Kapojos JJ: Protease activity of plasma hemopexin. Kidney Int 2005; 68:603-610. (Pubitemid 43323115)
10. Wei C, Saleem M, Goes N, Reiser J: Soluble urokinase receptor is a circulating glomerular disease recurrence factor. J Am Soc Nephrol 2008; 19:103A.
11. Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J: Modification of kidney barrier function by the urokinase receptor. Nat Med 2008; 14: 55-63.
12. Savin VJ, Sharma M: Plasma "factors" in recurrent nephrotic syndrome after kidney transplantation: causes or consequences of glomerular injury? Am J Kidney Dis 2009;54:406-409.
13. Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, Hurault de Ligny B, Niaudet P, Charpentier B, Soulillou JP: Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 33: 7-14.
14. Gohh RY, Yango AF, Morrissey PE, Monaco AP, Gautam A, Sharma M, McCarthy ET, Savin VJ: Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 2005; 12: 2907-2912. (Pubitemid 43923951)
15. Gonzalez E, Ettenger R, Rianthavorn P, Tsai E, Malekzadeh M: Preemptive plasmapher-esis and recurrence of focal segmental glo-merulosclerosis in pediatric renal transplantation. Pediatr Transplant 2011; 15:495-501.
16. International Study of Kidney Disease in Children: Cyclophosphamide therapy in focal segmental glomerular sclerosis: a controlled clinical trial. Eur J Pediatr 1983; 140:149.
17. Mendoza SA, Reznik VM, Griswold WR, Krensky AM, Yorgin PD, Tune BM: Treatment of steroid-resistant focal segmental glo-merulosclerosis with pulse methylpredniso-lone and alkylating agents. Pediatr Nephrol 1990; 4:303-307. (Pubitemid 20252779)
18. Niaudet P, Habib R: Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol 1994; 5:1049-1056. (Pubitemid 24977081)
19. Mättö M, Raunio AR, Postila V, Huttunen K, Hirvonen MR, Pelkonen J: Human B cells and macrophages cooperate in T-cell-inde-pendent type 2 response. Scand J Immunol 2008; 67:209-217. (Pubitemid 351197158)
20. Prytuła A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R, Ognjanovic M, Filler G, Smith G, Tullus K: Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 2010; 25:461-468.
21. Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, Deschênes G, Ronco PM, Plaisier EM, Dahan KY: Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 2013 (E-pub ahead of print).
22. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL: Progressive multifocal leukoencephalopathy after ritux-imab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834-4840.
23. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P: The actin cytoskeleton of kidney podocytes is a direct target of the antiprotein-uric effect of cyclosporine A. Nat Med 2008; 14:931-938.
24. Sharma R, Sharma M, Ge X, McCarthy ET, Savin VJ: Cyclosporine protects glomeruli from FSGS factor via an increase in glomeru-lar cAMP. Transplantation 1996; 62:1916-1920. (Pubitemid 27014562)
25. Ransom RF, Lam NG, Hallett MA, et al: Glu-cocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int 2005; 68:2473-2483. (Pubitemid 43250994)
26. Canaud G, Zuber J, Sberro R, Royale V, An-glicheau D, Snanoudj R, Gaha K, Thervet E, Lefrère F, Cavazzana-Calvo M, Noël LH, Méjean A, Legendre CH, Martinez F: Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study. Am J Transplant 2009; 9:1081-1086.
27. Ristola M, Arpiainen S, Saleem MA, et al: Regulation of Neph3 gene in podocytes-key roles of transcription factors NF-κB and Sp1. BMC Mol Biol 2009; 10:83.
28. Sahali D, Pawlak A, Le Gouvello S, Lang P, Valanciuté A, Remy P, Loirat C, Niaudet P, Bensman A, Guellaen G: Transcriptional and post-transcriptional alterations of IκBα in active minimal-change nephrotic syndrome. J Am Soc Nephrol 2001; 12:1648-1658. (Pubitemid 32674427)
29. Audard V, Pawlak A, Candelier M, Lang P, Sahali D: Upregulation of nuclear factor-related κB suggests a disorder of transcriptional regulation in minimal change nephrotic syndrome. PLoS One 2012; 7:e30523.
30. Mansour H, Cheval L, Elalouf JM, Aude JC, Alyanakian MA, Mougenot B, Doucet A, Deschênes G: T-cell transcriptome analysis points up a thymic disorder in idiopathic ne-phrotic syndrome. Kidney Int 2005; 67:2168-2177. (Pubitemid 41623378)
31. Ruland J: Return to homeostasis: downregu-lation of NF-κB responses. Nat Immunol 2011; 12:709-714.
32. Fuchs O: Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies. Curr Mol Pharmacol 2010; 3:98-122.
33. La Porte CJ: Saquinavir, the pioneer antiret-roviral protease inhibitor. Expert Opin Drug Metab Toxicol 2009; 5:1313-1322.
34. Piccinini M, Rinaudo MT, Chiapello N, Ricotti E, Baldovino S, Mostert M, Tovo PA: The human 26S proteasome is a target of an-tiretroviral agents. AIDS 2002; 16:693-700. (Pubitemid 34274459)
35. Coppo R, Camilla R, Porcellini MG, Peruzzi L, Gianoglio B, Amore A, Daprà V, Loiacono E, Fonsato V, Dal Canton A, Esposito C, Es-posito P, Tovo PA: Saquinavir in steroid-dependent and-resistant nephrotic syndrome: a pilot study. Nephrol Dial Transplant 2012; 27: 1902-1910.
36. Brinkman K, Huysmans F, Burger DM: Phar-macokinetic interaction between saquinavir and cyclosporine. Ann Intern Med 1998; 129: 914-915.
37. Reiser J, von Gersdorff G, Loos M, Oh J, Asa-numa K, Giardino L, Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M, Davidson A, Sugimoto H, Kalluri R, Sharpe AH, Kreidberg JA, Mundel P: Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004; 113: 1390-1397. (Pubitemid 39071694)
38. Bruggeman LA, Drawz PE, Kahoud N, Lin K, Barisoni L, Nelson PJ: TNFR2 interposes the proliferative and NF-κB-mediated inflammatory response by podocytes to TNF-α. Lab Invest 2011; 91:413-425.
39. Garside H, Stevens A, Farrow S, Normand C, Houle B, Berry A, Maschera B, Ray D: Gluco-corticoid ligands specify different interactions with NF-κB by allosteric effects on the glucocorticoid receptor DNA binding domain. J Biol Chem 2004; 279:50050-50059. (Pubitemid 39577816)
40. Meyer S, Kohler NG, Joly A: Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-κB activation. FEBS Lett 1997;413:354-358. (Pubitemid 27353299)